Pricing Log in Create free account
Saturday 17 October 2026 Export CMMB’s income statement to Excel — free account

Chemomab Therapeutics Ltd. Sponsored ADR

CMMB Healthcare Biotechnology

In the quarter to June 2026, EPS grew 25.0% and free cash flow grew 47.9%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

1.27 0.02 −1.55%
Market cap
$9.4M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Chemomab Therapeutics Ltd. Sponsored ADR (CMMB) Business Profile

Updated before January 2025

Company Overview

Chemomab Therapeutics Ltd. Sponsored ADR (CMMB) is a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases. Founded in 2011 and headquartered in Tel Aviv, Israel, Chemomab leverages its proprietary platform to address unmet medical needs in conditions characterized by fibrosis and inflammation. The company is led by an experienced management team, including Dr. Adi Mor, the Co-Founder and Chief Executive Officer, who brings extensive expertise in immunology and drug development. Other key leadership figures include Dr. Adi Goldiner, Chief Medical Officer, and Dr. Gil Efron, Chief Financial Officer, who collectively drive the company’s strategic vision and operational execution.

Chemomab is listed on the NASDAQ under the ticker symbol CMMB, and its Sponsored ADRs provide global investors with access to its innovative pipeline and growth potential. The company’s mission is to transform the lives of patients suffering from debilitating fibrotic and inflammatory diseases by developing targeted therapies that address the underlying causes of these conditions.

Core Business Segments

Chemomab Therapeutics operates primarily in the biotechnology and pharmaceutical sectors, with a focus on developing monoclonal antibody-based therapies. The company’s core business segments include:

1. Therapeutic Development

Chemomab’s flagship product candidate is CM-101, a first-in-class monoclonal antibody designed to target CCL24, a chemokine implicated in the development of fibrosis and inflammation. CM-101 is being developed for multiple indications, including:

  • Primary Sclerosing Cholangitis (PSC): A rare, chronic liver disease characterized by inflammation and fibrosis of the bile ducts.
  • Systemic Sclerosis (SSc): A severe autoimmune disease that leads to widespread fibrosis and vascular damage.
  • Lung Fibrosis: A condition marked by scarring and stiffening of lung tissue, impairing respiratory function.

2. Research and Development (R&D)

Chemomab invests heavily in R&D to expand its pipeline of innovative therapies. The company employs advanced technologies to identify and validate novel targets for fibrotic and inflammatory diseases. Its R&D efforts are supported by collaborations with leading academic institutions and industry partners.

3. Clinical Trials

Chemomab conducts rigorous clinical trials to evaluate the safety and efficacy of its product candidates. The company is currently advancing CM-101 through Phase 2 clinical trials for PSC and SSc, with promising preliminary results that underscore its potential as a transformative therapy.

Business Model

Chemomab’s business model is centered on the development and commercialization of novel therapeutics for niche markets with high unmet medical needs. The company generates revenue through:

  • Licensing Agreements: Partnering with pharmaceutical companies to co-develop and commercialize its therapies.
  • Collaborations: Establishing strategic alliances with academic and industry stakeholders to accelerate drug development.
  • Grants and Funding: Securing non-dilutive funding from government agencies and research organizations to support its R&D initiatives.

Chemomab’s approach integrates cutting-edge science, robust clinical development, and strategic partnerships to create value for patients, healthcare providers, and investors.

Strategic Direction

Chemomab is committed to advancing its pipeline of innovative therapies and achieving long-term growth. Key elements of its strategic direction include:

  • Pipeline Expansion: Exploring additional indications for CM-101 and identifying new therapeutic targets for fibrotic and inflammatory diseases.
  • Global Market Penetration: Expanding its presence in key markets, including North America, Europe, and Asia.
  • Sustainability Goals: Implementing environmentally responsible practices in its operations and supply chain.
  • Innovation: Leveraging emerging technologies, such as artificial intelligence and machine learning, to enhance drug discovery and development.

Competitive Landscape

Chemomab operates in a competitive biotechnology sector, facing competition from both established pharmaceutical companies and emerging biotech firms. Key competitors include:

  • Intercept Pharmaceuticals: Focused on liver diseases, including PSC.
  • FibroGen: Specializes in therapies for fibrotic diseases.
  • Galapagos NV: Develops treatments for inflammatory and fibrotic conditions.
  • Genfit: A biotechnology company targeting liver and metabolic diseases.

Chemomab differentiates itself through its proprietary approach to targeting CCL24 and its focus on rare and underserved diseases.

Risk Factors

Chemomab faces several risks that could impact its operations and financial performance, including:

  • Regulatory Risks: Delays or failures in obtaining regulatory approvals for its product candidates.
  • Market Dependence: Reliance on the success of CM-101 as its primary revenue driver.
  • Supply Chain Disruptions: Potential challenges in sourcing raw materials and manufacturing its therapies.
  • Competition: Intense competition from larger pharmaceutical companies with greater resources.
  • Clinical Trial Risks: Uncertainty surrounding the outcomes of ongoing and future clinical trials.

Recent Developments

Chemomab has made significant progress in advancing its pipeline and corporate strategy. Recent developments include:

  • Clinical Trial Milestones: Completion of Phase 2a trials for CM-101 in PSC, demonstrating favorable safety and efficacy profiles.
  • Partnerships: Collaboration with leading academic institutions to explore new therapeutic targets.
  • Corporate Initiatives: Strengthening its leadership team with the appointment of seasoned executives to key roles.
  • Global Developments: Navigating the challenges posed by the COVID-19 pandemic while maintaining operational continuity.

Investment Considerations

Investors considering Chemomab Therapeutics should weigh the following factors:

Strengths

  • Innovative Pipeline: A promising product candidate with potential applications across multiple indications.
  • Experienced Leadership: A management team with deep expertise in drug development and commercialization.
  • Market Opportunity: Targeting rare diseases with significant unmet medical needs.

Risks

  • Clinical and Regulatory Uncertainty: Dependence on successful clinical trial outcomes and regulatory approvals.
  • Financial Risks: Limited revenue generation and reliance on external funding.
  • Competitive Pressures: Operating in a highly competitive and rapidly evolving industry.

Conclusion

Chemomab Therapeutics Ltd. is a pioneering biotechnology company with a strong focus on developing therapies for fibrotic and inflammatory diseases. With its innovative pipeline, experienced leadership, and commitment to addressing unmet medical needs, Chemomab is well-positioned for growth. However, investors should carefully consider the risks associated with clinical-stage biotech companies. As Chemomab advances its pipeline and explores new opportunities, it has the potential to make a meaningful impact on patients’ lives and deliver value to its stakeholders.